StockViz
Share URL
Embed chart view
-
Export .csv
-
Download image
-
Copy link
-
Embed code
StockViz
RANKINGS
AbbVie Inc.
NYSE:ABBV
Sector
Location
Market Cap
USD 334.34 B
Share Price
USD 189.28
Avg Daily Volume
7,907,546
Change (1 day)
-0.77%
Change (1 year)
15.53%
Change (YTD)
6.52%
AbbVie Inc. Enterprise Value to EBITDA (EV/EBITDA) on July 03, 2025: 24.22
AbbVie Inc. Enterprise Value to EBITDA (EV/EBITDA) is 24.22 on July 03, 2025, a 70.15% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.
-
AbbVie Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 26.37 on July 03, 2025, which is 8.88% above the current Enterprise Value to EBITDA (EV/EBITDA).
-
AbbVie Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 14.34 on July 03, 2025, which is -40.81% below the current Enterprise Value to EBITDA (EV/EBITDA).
-
AbbVie Inc. average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 19.07.
Competitors
Eli Lilly and Company
USD 780.67
LLY
+1.39
0.18%
Roche Holding AG
USD 347.79
RO.SW
+3.30
0.96%
AstraZeneca PLC
USD 140.96
AZN.L
+1.64
1.18%
Merck & Co., Inc.
USD 80.93
MRK
-1.46
-1.77%
Amgen Inc.
USD 298.24
AMGN
+1.39
0.47%
Pfizer Inc.
USD 25.38
PFE
+0.06
0.24%
Gilead Sciences, Inc.
USD 111.75
GILD
+0.24
0.21%
Sanofi
USD 98.03
SAN.PA
+1.08
1.11%
Bristol-Myers Squibb Company
USD 46.92
BMY
-0.71
-1.49%
Chugai Pharmaceutical Co., Ltd.
USD 49.30
4519.T
+0.76
1.57%
GSK plc
USD 19.16
GSK.L
+0.13
0.68%
Regeneron Pharmaceuticals, Inc.
USD 547.36
REGN
-0.38
-0.07%
Cencora, Inc.
USD 296.23
COR
+5.06
1.74%
Jiangsu Hengrui Medicine Co., Ltd.
USD 7.43
600276.SS
+0.11
1.54%
Takeda Pharmaceutical Company Limited
USD 30.72
4502.T
+0.21
0.69%
Haleon plc
USD 5.15
HLN.L
+0.06
1.17%
Daiichi Sankyo Company, Limited
USD 22.30
4568.T
+0.05
0.21%
UCB SA
USD 198.80
UCB.BR
+6.47
3.36%
Hansoh Pharmaceutical Group Company Limited
USD 3.97
3692.HK
+0.09
2.44%
Teva Pharmaceutical Industries Limited
USD 17.20
TEVA.TA
+0.20
1.20%
Key Data
| Date | Enterprise Value to EBITDA (EV/EBITDA) | Free Cash Flow Yield | Dividend Yield | Market Capitalization |
|---|
Competitors
Eli Lilly and Company
USD 780.67
LLY
+1.39
0.18%
Roche Holding AG
USD 347.79
RO.SW
+3.30
0.96%
AstraZeneca PLC
USD 140.96
AZN.L
+1.64
1.18%
Merck & Co., Inc.
USD 80.93
MRK
-1.46
-1.77%
Amgen Inc.
USD 298.24
AMGN
+1.39
0.47%
Pfizer Inc.
USD 25.38
PFE
+0.06
0.24%
Gilead Sciences, Inc.
USD 111.75
GILD
+0.24
0.21%
Sanofi
USD 98.03
SAN.PA
+1.08
1.11%
Bristol-Myers Squibb Company
USD 46.92
BMY
-0.71
-1.49%
Chugai Pharmaceutical Co., Ltd.
USD 49.30
4519.T
+0.76
1.57%
GSK plc
USD 19.16
GSK.L
+0.13
0.68%
Regeneron Pharmaceuticals, Inc.
USD 547.36
REGN
-0.38
-0.07%
Cencora, Inc.
USD 296.23
COR
+5.06
1.74%
Jiangsu Hengrui Medicine Co., Ltd.
USD 7.43
600276.SS
+0.11
1.54%
Takeda Pharmaceutical Company Limited
USD 30.72
4502.T
+0.21
0.69%
Haleon plc
USD 5.15
HLN.L
+0.06
1.17%
Daiichi Sankyo Company, Limited
USD 22.30
4568.T
+0.05
0.21%
UCB SA
USD 198.80
UCB.BR
+6.47
3.36%
Hansoh Pharmaceutical Group Company Limited
USD 3.97
3692.HK
+0.09
2.44%
Teva Pharmaceutical Industries Limited
USD 17.20
TEVA.TA
+0.20
1.20%